Statistical analysis showed significant differences with regard to mean E3 values between patients and controls (p = 0.045; mixed-model analysis of variance (ANOVA) test). Mean FA was EPZ5676 cell line lower, and mean MD, mean E1, and mean E2 were higher in each measured ROI in patients compared to controls, but these differences were not statistically significant.
Asymptomatic HIV-positive patients demonstrate only subtle changes in DTI metrics measured in the cervical spinal cord compared to healthy volunteers that currently do not support using DTI as a diagnostic tool for the early detection of HIVM.”
“New
coils with unproven clinical benefit enlarge the armamentarium for endovascular aneurysm treatment continuously. Large patient numbers needed to detect benefits of such new techniques prevent timely evaluation of efficacy. We propose measuring the volume of aneurysm recurrences as surrogate endpoint for coil stability. We hypothesize that this method allows detecting effects of new materials with reduced sample sizes in comparison to conventional studies with dichotomous endpoints.
Institutional review board approval and informed consent were obtained. Fifty-nine patients with decreasing aneurysm size and at least two available
follow-up time-of-flight magnetic resonance angiographies (ToF-MRAs) were included. Newly developed
software for measuring aneurysm volume differences based on ToF-MRA images was used. Based on the observed crotamiton recurrence volumes and retreatment rates, the sample Everolimus research buy size for future studies comparing standard versus “”new coils”" were calculated.
Mean recurrence volume was 38.92 mu l (SD110.85 mu l). To show a 50% reduction of retreatment rate to control (p = 0.05; power 80%) in a regular study (dichotomous endpoint), the required sample size would be n = 356 compared with n = 78 if using the continuous surrogate endpoint “”recurrence volume”". When extrapolating our data to data given in the literature, sample sizes could be reduced from n = 948 to n = 74 without loss of statistical power.
Further studies on new materials using volumetric analysis based on ToF-MRA as surrogate endpoint could substantially decrease sample size and allow a more timely assessment of possible benefit of new materials with a fraction of the cost.”
“The Woven Endobridge (WEB II) device (Sequent Medical, Inc., Aliso Viejo, CA, USA) is an intra-saccular, oblate, braided-wire embolization device designed to provide flow disruption at the aneurysm neck-parent artery interface. The purpose of this study was to evaluate the acute and short-term performance of the WEB II device regarding the immediacy, degree, and durability of aneurysm occlusion in two patients.